{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-023500","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.763575+00:00","generated_at":"2026-05-17T13:57:35.411711+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ensysce Biosciences reports Q2 2025 net loss of $1.7M, advances Phase 3 trial for PF614","bullets":["Cash and equivalents $2.2M at June 30, 2025, down from $3.5M at Dec 31, 2024.","Net loss $1.7M in Q2 2025 vs $2.0M loss in Q2 2024; R&D expenses rose to $1.9M from $0.9M.","Federal grant revenue $1.4M in Q2 2025 vs $0.2M in Q2 2024, driven by MPAR study activity.","Initiated pivotal Phase 3 trial (PF614-301) for post-surgical pain; Rho, Inc. engaged as CRO.","Received $5.3M NIDA installment and U.S. patent allowance for OUD candidate PF9001."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-023500","json":"https://secwatch.observer/filing/0001641172-25-023500.json","markdown":"https://secwatch.observer/filing/0001641172-25-023500.md","text":"https://secwatch.observer/filing/0001641172-25-023500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000164117225023500/0001641172-25-023500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000164117225023500/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:57:35.411711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}